Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 13-14/2019

06.03.2018 | main topic

The value of metastasectomy in stage IV cutaneous melanoma

verfasst von: Prof. Dr. Uwe Wollina, MD, Piotr Brzezinski

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2019

Einloggen, um Zugang zu erhalten

Summary

Cutaneous melanoma is an aggressive neoplasia of melanocytes. Prognosis is dependent on tumor stage. Stage IV melanoma is characterized by the occurrence of distant metastases. Response of metastases to classical chemotherapy is limited and toxicity of treatment is high. In recent years, new developments in immunotherapy and targeted therapies improved prognosis of stage IV melanoma patients with better tolerability of treatment. There is no dispute about surgical treatment of primary melanoma. But what is the value of metastasectomy in the era of new systemic treatments? This review aims to discuss available data for surgical removal of distant metastases for several organs and tissues. The available evidence suggests that for selected patients with possible complete resection of all tumor metastases, metastasectomy remains an effective treatment option with a benefit in overall survival.
Literatur
1.
Zurück zum Zitat Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol. 2006;19(Suppl 2):S41–S70.CrossRefPubMed Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol. 2006;19(Suppl 2):S41–S70.CrossRefPubMed
2.
Zurück zum Zitat Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–40.PubMed Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–40.PubMed
3.
Zurück zum Zitat Berwick M, Buller DB, Cust A, et al. Melanoma epidemiology and prevention. Cancer Treat Res. 2016;167:17–49.CrossRefPubMed Berwick M, Buller DB, Cust A, et al. Melanoma epidemiology and prevention. Cancer Treat Res. 2016;167:17–49.CrossRefPubMed
5.
Zurück zum Zitat Lugowska I, Szkultecka-Dębek M, Sozańska-Solak A, et al. Stage III/IV melanoma in Poland: epidemiology, standard of care and treatment related costs. J Health Policy Outcomes Res. 2012;2(2):41–7. Lugowska I, Szkultecka-Dębek M, Sozańska-Solak A, et al. Stage III/IV melanoma in Poland: epidemiology, standard of care and treatment related costs. J Health Policy Outcomes Res. 2012;2(2):41–7.
6.
Zurück zum Zitat Testori A, Ribero S, Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol. 2017;43(3):544–60.CrossRefPubMed Testori A, Ribero S, Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol. 2017;43(3):544–60.CrossRefPubMed
7.
Zurück zum Zitat Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17(1):129–37.CrossRefPubMed Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17(1):129–37.CrossRefPubMed
8.
Zurück zum Zitat Beger J, Hansel G, Krönert C, et al. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013;52(2):220–30.CrossRefPubMed Beger J, Hansel G, Krönert C, et al. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013;52(2):220–30.CrossRefPubMed
9.
Zurück zum Zitat Satzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol. 2011;18(2):514–20.CrossRefPubMed Satzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol. 2011;18(2):514–20.CrossRefPubMed
10.
Zurück zum Zitat Geimer T, Sattler EC, Flaig MJ, et al. The impact of sentinel node dissection on disease-free and overall tumour-specific survival in melanoma patients: a single centre group-matched analysis of 1192 patients. J Eur Acad Dermatol Venereol. 2017;31(4):629–35.CrossRefPubMed Geimer T, Sattler EC, Flaig MJ, et al. The impact of sentinel node dissection on disease-free and overall tumour-specific survival in melanoma patients: a single centre group-matched analysis of 1192 patients. J Eur Acad Dermatol Venereol. 2017;31(4):629–35.CrossRefPubMed
11.
Zurück zum Zitat Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2.CrossRefPubMedPubMedCentral Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.CrossRefPubMed Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.CrossRefPubMed
13.
Zurück zum Zitat Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.CrossRefPubMedPubMedCentral Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bartlett EK, Simmons KD, Wachtel H, et al. The rise in metastasectomy across cancer types over the past decade. Cancer. 2015;121(5):747–57.CrossRefPubMed Bartlett EK, Simmons KD, Wachtel H, et al. The rise in metastasectomy across cancer types over the past decade. Cancer. 2015;121(5):747–57.CrossRefPubMed
15.
Zurück zum Zitat Tronnier M, Semkova K, Wollina U, Tchernev G. Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach. Wien Med Wochenschr. 2013;163(15–16):354–8.CrossRefPubMed Tronnier M, Semkova K, Wollina U, Tchernev G. Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach. Wien Med Wochenschr. 2013;163(15–16):354–8.CrossRefPubMed
16.
17.
Zurück zum Zitat Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–55.CrossRefPubMedPubMedCentral Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–55.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK. Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol. 2017;143(3):533–40.CrossRefPubMed Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK. Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol. 2017;143(3):533–40.CrossRefPubMed
19.
Zurück zum Zitat Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111–5.CrossRefPubMedPubMedCentral Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111–5.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Deutsch GB, Flaherty DC, Kirchoff DD, et al. Association of surgical treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965–2014: Relevance of surgical cure in the era of modern systemic therapy. Jama Surg. 2017;152(7):672–8.CrossRefPubMedPubMedCentral Deutsch GB, Flaherty DC, Kirchoff DD, et al. Association of surgical treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965–2014: Relevance of surgical cure in the era of modern systemic therapy. Jama Surg. 2017;152(7):672–8.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Collinson FJ, Lam TK, Bruijn WM, et al. Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy. Ann Surg Oncol. 2008;15(6):1741–9.CrossRefPubMed Collinson FJ, Lam TK, Bruijn WM, et al. Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy. Ann Surg Oncol. 2008;15(6):1741–9.CrossRefPubMed
22.
Zurück zum Zitat Flaherty DC, Deutsch GB, Kirchoff DD, et al. Adrenalectomy for metastatic melanoma: current role in the age of nonsurgical treatments. Am Surg. 2015;81(10):1005–9.PubMedPubMedCentral Flaherty DC, Deutsch GB, Kirchoff DD, et al. Adrenalectomy for metastatic melanoma: current role in the age of nonsurgical treatments. Am Surg. 2015;81(10):1005–9.PubMedPubMedCentral
23.
Zurück zum Zitat Ryu SW, Saw R, Scolyer RA, Crawford M, Thompson JF, Sandroussi C. Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. J Surg Oncol. 2013;108(2):129–35.CrossRefPubMed Ryu SW, Saw R, Scolyer RA, Crawford M, Thompson JF, Sandroussi C. Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. J Surg Oncol. 2013;108(2):129–35.CrossRefPubMed
24.
Zurück zum Zitat Zekri J, Marples M, Taylor D, Kandukurti K, McParland L, Brown JE. Complications of bone metastases from malignant melanoma. J Bone Oncol. 2017;8:13–7.CrossRefPubMedPubMedCentral Zekri J, Marples M, Taylor D, Kandukurti K, McParland L, Brown JE. Complications of bone metastases from malignant melanoma. J Bone Oncol. 2017;8:13–7.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Colman MW, Kirkwood JM, Schott T, Goodman MA, McGough RL 3rd. Does metastasectomy improve survival in skeletal melanoma? Melanoma Res. 2014;24(4):354–9.CrossRefPubMed Colman MW, Kirkwood JM, Schott T, Goodman MA, McGough RL 3rd. Does metastasectomy improve survival in skeletal melanoma? Melanoma Res. 2014;24(4):354–9.CrossRefPubMed
26.
Zurück zum Zitat Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117(8):1697–703.CrossRefPubMed Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117(8):1697–703.CrossRefPubMed
27.
Zurück zum Zitat Pessina F, Navarria P, Cozzi L, et al. Role of surgical resection in patients with single large brain metastases: feasibility, morbidity, and local control evaluation. World Neurosurg. 2016;94:6–12.CrossRefPubMed Pessina F, Navarria P, Cozzi L, et al. Role of surgical resection in patients with single large brain metastases: feasibility, morbidity, and local control evaluation. World Neurosurg. 2016;94:6–12.CrossRefPubMed
29.
Zurück zum Zitat Brown RE, Ross MI, Edwards MJ, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2010;17(12):3330–5.CrossRefPubMed Brown RE, Ross MI, Edwards MJ, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2010;17(12):3330–5.CrossRefPubMed
30.
Zurück zum Zitat Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(4):450–73.CrossRefPubMed Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(4):450–73.CrossRefPubMed
31.
Zurück zum Zitat Delgado AF, Delgado AF. Complete lymph node dissection in melanoma: a systematic review and meta-analysis. Anticancer Res. 2017;37(12):6825–9.PubMed Delgado AF, Delgado AF. Complete lymph node dissection in melanoma: a systematic review and meta-analysis. Anticancer Res. 2017;37(12):6825–9.PubMed
32.
Zurück zum Zitat Treasure T, Milošević M, Fiorentino F, Macbeth F. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014;69(10):946–9.CrossRefPubMed Treasure T, Milošević M, Fiorentino F, Macbeth F. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014;69(10):946–9.CrossRefPubMed
33.
Zurück zum Zitat Schuhan C, Muley T, Dienemann H, Pfannschmidt J. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg. 2011;59(3):158–62.CrossRefPubMed Schuhan C, Muley T, Dienemann H, Pfannschmidt J. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg. 2011;59(3):158–62.CrossRefPubMed
34.
Zurück zum Zitat Younes R, Abrao FC, Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res. 2013;23(4):307–11.PubMed Younes R, Abrao FC, Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res. 2013;23(4):307–11.PubMed
35.
Zurück zum Zitat Chua TC, Scolyer RA, Kennedy CW, Yan TD, McCaughan BC, Thompson JF. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol. 2012;19(6):1774–81.CrossRefPubMed Chua TC, Scolyer RA, Kennedy CW, Yan TD, McCaughan BC, Thompson JF. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol. 2012;19(6):1774–81.CrossRefPubMed
36.
Zurück zum Zitat Guerrini GP, Lo Faso F, Vagliasindi A, et al. The role of minimally invasive surgery in the treatment of lung metastases. J Invest Surg. 2017;30(2):110–5.CrossRefPubMed Guerrini GP, Lo Faso F, Vagliasindi A, et al. The role of minimally invasive surgery in the treatment of lung metastases. J Invest Surg. 2017;30(2):110–5.CrossRefPubMed
37.
Zurück zum Zitat Lo Faso F, Solaini L, Lembo R, et al. Thoracoscopic lung metastasectomies: a 10-year, single-center experience. Surg Endosc. 2013;27(6):1938–44.CrossRefPubMedPubMedCentral Lo Faso F, Solaini L, Lembo R, et al. Thoracoscopic lung metastasectomies: a 10-year, single-center experience. Surg Endosc. 2013;27(6):1938–44.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Abdelnour-Berchtold E, Perentes JY, Ris HB, et al. Survival and local recurrence after video-assisted thoracoscopic lung metastasectomy. World J Surg. 2016;40(2):373–9.CrossRefPubMed Abdelnour-Berchtold E, Perentes JY, Ris HB, et al. Survival and local recurrence after video-assisted thoracoscopic lung metastasectomy. World J Surg. 2016;40(2):373–9.CrossRefPubMed
39.
Zurück zum Zitat Eckardt J, Licht PB. Thoracoscopic versus open pulmonary metastasectomy: a prospective, sequentially controlled study. Chest. 2012;142(6):1598–602.CrossRefPubMed Eckardt J, Licht PB. Thoracoscopic versus open pulmonary metastasectomy: a prospective, sequentially controlled study. Chest. 2012;142(6):1598–602.CrossRefPubMed
40.
Zurück zum Zitat Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14(10):2847–53.CrossRefPubMed Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14(10):2847–53.CrossRefPubMed
41.
Zurück zum Zitat Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca Cancer J Clin. 2017;67(6):472–92.CrossRefPubMedPubMedCentral Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca Cancer J Clin. 2017;67(6):472–92.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Garbe C, Peris K, Hauschild A, et al. European consensus-based interdisciplinary guideline—update. Eur J Cancer. 2016;2016(63):201–17.CrossRef Garbe C, Peris K, Hauschild A, et al. European consensus-based interdisciplinary guideline—update. Eur J Cancer. 2016;2016(63):201–17.CrossRef
43.
44.
Zurück zum Zitat Austin E, Mamalis A, Ho D, Jagdeo J. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. Arch Dermatol Res. 2017;309(4):229–42.CrossRefPubMed Austin E, Mamalis A, Ho D, Jagdeo J. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. Arch Dermatol Res. 2017;309(4):229–42.CrossRefPubMed
45.
Zurück zum Zitat Amaral T, Tampouri I, Garbe C. How to use neoadjuvant medical treatment to maximize surgery in melanoma. Expert Rev Anticancer Ther. 2018;18(2):121–30.CrossRefPubMed Amaral T, Tampouri I, Garbe C. How to use neoadjuvant medical treatment to maximize surgery in melanoma. Expert Rev Anticancer Ther. 2018;18(2):121–30.CrossRefPubMed
46.
Zurück zum Zitat Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(26):e7325.CrossRef Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(26):e7325.CrossRef
47.
Zurück zum Zitat Baker JJ, Stitzenberg KB, Collichio FA, Meyers MO, Ollila DW. Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab. Am Surg. 2014;80(8):805–10.PubMed Baker JJ, Stitzenberg KB, Collichio FA, Meyers MO, Ollila DW. Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab. Am Surg. 2014;80(8):805–10.PubMed
48.
Zurück zum Zitat Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991–4000.CrossRefPubMed Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991–4000.CrossRefPubMed
49.
Zurück zum Zitat Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2017;24(1):135–41.CrossRefPubMed Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2017;24(1):135–41.CrossRefPubMed
50.
Zurück zum Zitat Najem A, Krayem M, Perdrix A, et al. New drug combination strategies in melanoma: current status and future directions. Anticancer Res. 2017;37(11):5941–53.PubMed Najem A, Krayem M, Perdrix A, et al. New drug combination strategies in melanoma: current status and future directions. Anticancer Res. 2017;37(11):5941–53.PubMed
51.
Zurück zum Zitat He M, Lovell J, Ng BL, et al. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. J Surg Oncol. 2015;111(8):980–4.CrossRefPubMed He M, Lovell J, Ng BL, et al. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. J Surg Oncol. 2015;111(8):980–4.CrossRefPubMed
52.
Zurück zum Zitat Zippel D, Markel G, Shapira-Frommer R, et al. Perioperative BRAF inhibitors in locally advanced stage III melanoma. J Surg Oncol. 2017;116(7):856–61.CrossRefPubMed Zippel D, Markel G, Shapira-Frommer R, et al. Perioperative BRAF inhibitors in locally advanced stage III melanoma. J Surg Oncol. 2017;116(7):856–61.CrossRefPubMed
54.
Zurück zum Zitat Raigani S, Cohen S, Boland GM. The role of surgery for melanoma in an era of effective systemic therapy. Curr Oncol Rep. 2017;19(3):17.CrossRefPubMed Raigani S, Cohen S, Boland GM. The role of surgery for melanoma in an era of effective systemic therapy. Curr Oncol Rep. 2017;19(3):17.CrossRefPubMed
55.
Zurück zum Zitat Wollina U. Late recurrence is a sign of melanoma dormancy: need of life-long follow-up of melanoma patients. In: Hayat MA, editor. Tumor dormancy, quescience, and senescence. Aging, cancer, and noncancer pathologies. Vol. 1. Dordrecht: Springer; 2013. pp. 79–83.CrossRef Wollina U. Late recurrence is a sign of melanoma dormancy: need of life-long follow-up of melanoma patients. In: Hayat MA, editor. Tumor dormancy, quescience, and senescence. Aging, cancer, and noncancer pathologies. Vol. 1. Dordrecht: Springer; 2013. pp. 79–83.CrossRef
Metadaten
Titel
The value of metastasectomy in stage IV cutaneous melanoma
verfasst von
Prof. Dr. Uwe Wollina, MD
Piotr Brzezinski
Publikationsdatum
06.03.2018
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2019
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-018-0630-6

Weitere Artikel der Ausgabe 13-14/2019

Wiener Medizinische Wochenschrift 13-14/2019 Zur Ausgabe

editorial

wmw history

editorial

Melanom